• 1
    Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005; 105: 26402653.
  • 2
    Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 24082417.
  • 3
    Loriaux M, Deininger M. Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma. 2004; 45: 21972203.
  • 4
    Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia. 2004; 18: 13401346.
  • 5
    O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 2003; 17: 481487.
  • 6
    Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome (Ph) negative metaphases appearing during treatment with imatinib mesylate in patients (pts) with Ph positive chronic myeloid leukemia (CML) in chronic phase (CP). [abstract]. Blood. 2002; 100: 368a.
  • 7
    McMullin MF, Humphreys M, Byrne J, Russell NH, Cuthbert RJ, O'Dwyer ME. Chromosomal abnormalities in Ph− cells of patients on imatinib. Blood. 2003; 102: 27002701.
  • 8
    Bumm T, Muller C, Al Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph− cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood. 2003; 101: 19411949.
  • 9
    Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood. 2006; 108: 28112813.
  • 10
    Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645652.
  • 11
    Bache I, Hasle H, Tommerup N, Olsen JH. Population-based study of cancer among carriers of a constitutional structural chromosomal rearrangement. Genes Chromosomes.Cancer. 2006; 45: 231246.
  • 12
    Marin D, Bua M, Marktel S, et al. The combination of cytogenetic response after 6 months treatment with STI571 and the presence of cytopenias in patients with CML in chronic phase resistant to or intolerant of interferon-alfa defines four different prognostic groups. [abstract]. Blood. 2001; 98: 846a.
  • 13
    Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004; 100: 116121.
  • 14
    Kantarjian HM, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002; 8: 21772187.
  • 15
    Snyder DS, Slovak ML, Bhatia R, Arber D. Philadelphia chromosome negative clones in Philadelphia chromosome positive CML: emerging clinical implications in eight cases. [abstract] Blood. 2002; 100: 322b.
  • 16
    Alimena G, Breccia M, Mancini M, et al. Clonal evolution in Philadelphia chromosome negative cells after successful treatment with imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome. Leukemia. 2004; 18: 361362.
  • 17
    Espinet B, Oliveira AC, Boque C, Domingo A, Alonso E, Sole F. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate. Haematologica. 2005; 90: 556558.
  • 18
    Perel JM, McCarthy C, Walker O, Irving I, Williams B, Kennedy GA. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate [case report]. Haematologica. 2005; 90( suppl): ECR25.
  • 19
    Mozziconacci MJ, Cailleres S, Maurice C, et al. Myelodysplastic features developing in Philadelphia-negative cells during imatinib mesylate therapy for CML: report of a new case. Leukemia. 2003; 17: 19011902.
  • 20
    Bacher U, Hochhaus A, Berger U, et al. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia. 2005; 19: 460463.
  • 21
    Wiktor A, Rybicki BA, Piao ZS, et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer. 2000; 27: 1116.
  • 22
    Fayad L, Kantarjian H, O'Brien S, et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia. 1997; 11: 767771.
  • 23
    Fabarius A, Giehl M, Frank O, et al. Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia. 2005; 19: 15731578.
  • 24
    Raskind WH, Ferraris AM, Najfeld V, Jacobson RJ, Moohr JW, Fialkow PJ. Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia. Leukemia. 1993; 7: 11631167.
  • 25
    Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Jacobson RJ, Hansen JA. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood. 1981; 58: 158163.
  • 26
    Royer-Pokora B, Hildebrandt B, Redmann A, et al. Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment. Leukemia. 2003; 17: 807810.
  • 27
    Meeus P, Demuynck H, Martiat P, Michaux L, Wouters E, Hagemeijer A. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with imatinib. Leukemia. 2003; 17: 465467.